Roth Capital Has Negative Forecast for MGRM Q1 Earnings

Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Free Report) - Equities researchers at Roth Capital reduced their Q1 2025 earnings per share estimates for shares of Monogram Orthopaedics in a note issued to investors on Wednesday, April 16th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.13) per share for the quarter, down from their prior forecast of ($0.10). The consensus estimate for Monogram Orthopaedics' current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics' Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.34) EPS and FY2028 earnings at $0.02 EPS.

Separately, Roth Mkm raised their price target on Monogram Orthopaedics from $4.00 to $5.40 and gave the stock a "buy" rating in a research report on Tuesday, March 18th.

Monogram Orthopaedics Stock Up 6.1 %

Shares of MGRM traded up $0.16 during mid-day trading on Friday, reaching $2.79. 14,643 shares of the company's stock were exchanged, compared to its average volume of 248,831. Monogram Orthopaedics has a 52-week low of $1.82 and a 52-week high of $4.21. The company has a market cap of $98.46 million, a price-to-earnings ratio of -5.94 and a beta of 0.77. The company has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.50.

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03.

Hedge Funds Weigh In On Monogram Orthopaedics

Several institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Monogram Orthopaedics during the 4th quarter worth $25,000. Northern Trust Corp boosted its stake in Monogram Orthopaedics by 110.6% in the 4th quarter. Northern Trust Corp now owns 45,873 shares of the company's stock worth $109,000 after buying an additional 24,088 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Monogram Orthopaedics by 286.6% in the 4th quarter. Wells Fargo & Company MN now owns 11,597 shares of the company's stock valued at $27,000 after buying an additional 8,597 shares during the period. Geode Capital Management LLC boosted its position in shares of Monogram Orthopaedics by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 226,378 shares of the company's stock worth $537,000 after acquiring an additional 16,234 shares during the last quarter. Finally, Orion Portfolio Solutions LLC purchased a new position in Monogram Orthopaedics during the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 0.45% of the company's stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.